10 years after implementation of TRIPS obligations in India.

The Patent (Amendment) Act of 2005 enforced after TRIPS raises many issues which hinder growth of Indian pharma companies. To tackle this, Indian pharma companies doubled their R&D expenditure and became significant players in global generic drug market. Indian pharmaceutical companies, which predominantly focused on import-oriented market, shifted to research-based approach by signing various agreements with MNCs that led to M&A and technology transfer.

Bioactive thermoresponsive polyblend nanofiber formulations for wound healing.

The rationale of this work is to develop new bioactive thermoresponsive polyblend nanofiber formulations for wound healing (topical). Various polymer compositions of thermoresponsive, poly(N-isopropylacrylamide), egg albumen and poly(ε-caprolactone) blend solutions with and without a drug [gatifloxacin hydrochloride, Gati] were prepared. Non-woven nanofibers of various compositions were fabricated using an electrospinning technique.